While visiting Tissue Engineering Group at Technical University of Catalonia in Barcelona in 2015, I've learnt news about pioneering therapies for bone cancers. Namely, an alternative therapy was found in cold plasmas generated at atmospheric pressure. They employed an atmospheric pressure plasma jet (APPJ) to test its selectivity towards osteosarcoma cell line vs. osteoblasts & human mesenchymal stem cells. Among major findings were delayed effects are observed which lead to 100% bone cancer cell death through apoptosis, while contact of APPJ with healthy cells did not lead to any affects. Authors speculated on an important role of the reactive oxygen species and reactive nitrogen species in the gaseous plasma stage and then transmitted to the liquid phase, - all leading to treatment of metastatic bone disease with that minimally invasive approach.